The European Commission has cleared, under the European Union Merger Regulation, the proposed purchase of health care major Abbott Laboratories' in vitro diagnostics business by fellow USA-based General Electric. Abbott Diagnostics is one of the world's leading suppliers of IVD products to the health care profession, and GE is also active in this sector. The Commission concluded that the new entity would not be able to restrict its downstream IVD rivals' access to key inputs and thus impede competition in the European Economic Area.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze